AI assistant
Sending…
BIO-RAD LABORATORIES, INC. — Director's Dealing 2011
Dec 16, 2011
30786_dirs_2011-12-16_b1cc4d10-c559-4a8d-b8c4-a6af7ab4ee8e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO RAD LABORATORIES INC (BIO, BIOB)
CIK: 0000012208
Period of Report: 2011-12-14
Reporting Person: SCHWARTZ NORMAN D (Director, CEO, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-12-14 | Bio-Rad B Common Stock | M | 2072 | $28.88 | Acquired | 93869 | Direct |
| 2011-12-14 | Bio-Rad B Common Stock | F | 1324 | $89.31 | Disposed | 92545 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-12-14 | Non-Qualified Stock Option (right to buy) | $28.88 | M | 2072 | Disposed | 2012-02-06 | Bio-Rad B Common Stock (2072) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Bio-Rad A Common Stock | 411252 | Direct |
| Bio-Rad B Common Stock | 12146 | Indirect |
| Bio-Rad B Common Stock | 4060054 | Indirect |
| Bio-Rad B Common Stock | 13726 | Indirect |
Footnotes
F1: The reporting person disclaims beneficial ownership of these shares.
F2: The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3: The shares are held by a limited partnership of which the reporting person is a limited partner.
F4: The stock option vested in five equal annual installments beginning on February 6, 2003.
More from BIO-RAD LABORATORIES, INC.
Regulatory Filings
2026
May 13
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Annual Report
2026
Mar 25
Proxy Solicitation & Information Statement
2026
Mar 25
Regulatory Filings
2026
Feb 19
Annual Report
2026
Feb 13